6533b830fe1ef96bd1297d63

RESEARCH PRODUCT

Prenatal exposure to perfluoroalkyl substances, immune-related outcomes, and lung function in children from a Spanish birth cohort study.

Thomas SchettgenMikel BasterretxeaMaribel CasasCyntia B. Manzano-salgadoMònica GuxensMireia GasconDavid MartinezJordi SunyerMaria-josé Lopez-espinosaMartine VrijheidFerran BallesterCarmen IñiguezCarlos ZabaletaBerit Granum

subject

SpirometryAdultVital capacityLongitudinal studyRespiratory diseasesEczemaPhysiology010501 environmental sciences01 natural sciences03 medical and health scienceschemistry.chemical_compound0302 clinical medicinePregnancyMedicineHumans030212 general & internal medicineImmune responseChildMaternal-Fetal ExchangeRespiratory Tract Infections0105 earth and related environmental sciencesAsthmaRespiratory SoundsPregnancyFluorocarbonsRespiratory tract infectionsmedicine.diagnostic_testbusiness.industryPublic Health Environmental and Occupational HealthInfantPrenatal exposure delayed effectsmedicine.diseaseAsthmaRespiratory Function TestsPerfluorooctanePerfluoroalkyl substanceschemistryAlkanesulfonic AcidsMaternal ExposureSpainRelative riskChild PreschoolPrenatal Exposure Delayed EffectsEnvironmental PollutantsFemaleCaprylatesbusinessBirth cohort

description

Background: Prenatal exposure to perfluoroalkyl substances (PFASs) has been associated with impaired immune and respiratory health during childhood but the evidence is inconsistent and limited for lung function. We studied the association between prenatal PFASs exposure and immune and respiratory health, including lung function, up to age 7 years in the Spanish INMA birth cohort study. Methods: We assessed four PFASs in maternal plasma samples collected during the 1st trimester of pregnancy (years: 2003-2008): perfluorohexane sulfonate (PFHxS), perfluorooctane sulfonate (PFOS), perfluorooctanoate (PFOA), and perfluorononanoate (PFNA). Mothers reported the occurrence (yes/no) of lower respiratory tract infections, wheezing, asthma, and eczema in the previous 12 months at 1.5 and 4 years of the child (n = 1188) and at 7 years (n = 1071). At ages 4 (n = 503) and 7 (n = 992) years lung function was assessed using spirometry tests. Results: The most abundant PFASs were PFOS and PFOA (geometric means: 5.80 and 2.31 ng/mL, respectively). The relative risk of asthma during childhood per each doubling in PFNA concentration was 0.74 (95 CI%: 0.57, 0.96). The relative risk of eczema during childhood per every doubling in PFOS concentration was 0.86 (95 CI%: 0.75, 0.98). Higher PFOA concentrations were associated with lower forced vital capacity and lower forced expiratory volume in 1 s z-scores at 4 years [beta (95 CI %): - 0.17 ( - 0.34, - 0.01) and - 0.13 ( - 0.29, 0.03), respectively], but not at 7 years. Conclusion: This longitudinal study suggests that different PFASs may affect the developing immune and respiratory systems differently. Prenatal exposure to PFNA and PFOS may be associated with reduced risk of respiratory and immune outcomes, particularly asthma and eczema whereas exposure to PFOA may be associated with reduced lung function in young children. These mixed results need to be replicated in follow-up studies at later ages.

10.1016/j.ijheh.2019.06.005https://pubmed.ncbi.nlm.nih.gov/31262703